Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  H. Lundbeck    LUN   DK0010287234

H. LUNDBECK (LUN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
06/18/2018 06/19/2018 06/20/2018 06/21/2018 06/22/2018 Date
470.3(c) 465.8(c) 470.6(c) 470(c) 474.1(c) Last
297 144 215 818 281 049 257 075 147 992 Volume
-1.18% -0.96% +1.03% -0.13% +0.87% Change
More quotes
Financials (DKK)
Sales 2018 18 052 M
EBIT 2018 5 715 M
Net income 2018 4 005 M
Finance 2018 5 739 M
Yield 2018 2,56%
Sales 2019 17 319 M
EBIT 2019 5 205 M
Net income 2019 3 671 M
Finance 2019 7 366 M
Yield 2019 2,63%
P/E ratio 2018 23,73
P/E ratio 2019 25,62
EV / Sales2018 4,91x
EV / Sales2019 5,02x
Capitalization 94 393 M
More Financials
Company
H. Lundbeck A/S engages in the research, development, and market of pharmaceutical products for the treatment of psychiatric and neurological disorders.It operates through the following geographical segments: Europe, the Unites States of America, and International Markets.Its product portfolio... 
Sector
Pharmaceuticals
Calendar
08/08Earnings Release
More about the company
Surperformance© ratings of H. Lundbeck
Trading Rating : Investor Rating :
More Ratings
Latest news on H. LUNDBECK
06/12TAKEDA PHARMACEUTICAL : Positive clinical phase III results of vortioxetine in J..
AQ
06/09TAKEDA PHARMACEUTICAL : Positive Clinical Phase III Results of Vortioxetine in J..
AQ
06/08H LUNDBECK : Positive clinical phase III results of vortioxetine in Japanese adu..
AQ
06/06Drugmaker Lundbeck to settle U.S. charity probe for $52.6 million
RE
06/06H LUNDBECK : Lundbeck reaches voluntary agreement in principle with U.S. Departm..
AQ
06/01H LUNDBECK : Lundbeck and Otsuka's Rxulti® (brexpiprazole) receives positive opi..
PU
05/31H LUNDBECK : Patent Issued for Process for the Manufacture of Idalopirdine via H..
AQ
05/25H LUNDBECK : Lundbeck increases its share capital by 41,946 shares as a result o..
AQ
05/23H LUNDBECK : Lundbeck increases its share capital by 41,946 shares (0.0211 % of ..
AQ
05/22H LUNDBECK : begins phase I-study of potential new treatment of schizophrenia & ..
AQ
More news
Sector news : Pharmaceuticals - NEC
06/22Federal Judge Gives Lilly Win on Alimta Regimen Patent
DJ
06/22JOHNSON & JOHNSON : Remakes Top Leadership -- Update
DJ
06/22JOHNSON & JOHNSON : Worldwide Chairman Peterson to Retire
DJ
06/22SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/22Roche to Appoint James Sabry as Head of Partnering
DJ
More sector news : Pharmaceuticals - NEC
Latest Tweets
06/11Analyzing Turning Point Brands $TPB and H. Lundbeck A/S- $HLUYY  
06/09H. Lundbeck A/S- $HLUYY versus Turning Point Brands $TPB Financial Review  
05/09$LUN #H. Lundbeck AS Lundbeck (Sell, TP: DKK360.00) -: Lundbeck (LUN DC, Sell.. 
05/08$OPNT Plc Orexo AB Insys Therapeutics Inc Indivior Plc H. Lundbeck AS Cereco.. 
05/08$LUN #H. Lundbeck AS Lundbeck (Sell, TP: DKK330.00) -: Lundbeck (LUN DC, Sell.. 
More tweets
Qtime:30
News from SeekingAlpha
05/09Lundbeck Thriving On Cost Control 
05/08H. Lundbeck A/S ADR reports Q1 results 
05/04Lundbeck Gets An Unexpected Boon From The FDA 
03/23Alzheon Files To Raise $80 Million In U.S. IPO 
03/16Lundbeck Pays Up For A New Clinical Trial Asset 
Chart H. LUNDBECK
Duration : Period :
H. Lundbeck Technical Analysis Chart | LUN | DK0010287234 | 4-Traders
Technical analysis trends H. LUNDBECK
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 17
Average target price 349  DKK
Spread / Average Target -26%
EPS Revisions
Managers
NameTitle
Anders Götzsche Executive VP, Chief Executive & Financial Officer
Lars Søren Rasmussen Chairman
Lars Bang Executive VP-Supply Operations & Engineering
Anders Gersel Pedersen Executive Vice President-Research & Development
Jørn Møller Mayntzhusen Director & Senior Manager-Supply Optimization
Sector and Competitors
1st jan.Capitalization (M$)
H. LUNDBECK49.21%14 761
JOHNSON & JOHNSON-12.27%329 475
PFIZER0.22%213 568
NOVARTIS-9.42%191 991
ROCHE HOLDING LTD.-12.58%191 785
MERCK AND COMPANY8.90%165 373